Plain-English translation of NCT05242744 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
Researchers are testing a new imaging scan called 18F-FluorThanatrace PET/CT that can measure a protein called PARP-1 in prostate cancer that has spread to other parts of your body. This is not a treatment study โ the scan itself won't change your cancer care decisions. Instead, doctors want to learn whether this imaging tool can help them understand which patients might benefit from certain types of cancer therapy, including PARP inhibitors, hormone therapy, or chemotherapy.
Currently, doctors don't have a good way to see which patients' cancers have high levels of the PARP-1 protein, which might help predict who will respond best to the medication. This study hopes to show that this new imaging scan could help personalize cancer treatment in the future.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will receive an injection of a radioactive tracer and then undergo a PET/CT scan from your head to mid-thigh about 60 minutes later. Most participants are also invited to have a second optional scan 1โ3 weeks after starting their new cancer treatment to see if the treatment changes what the scan shows. The study does not replace your regular cancer care โ your doctor will make all treatment decisions based on standard medical criteria, and the imaging results are for research purposes only.
AI-generated summary from trial data ยท Jul 15, 2026 ยท Not medical advice
United States